Member Info for Saxondale

A comment from the bottom of the RNS by Markku

We are continuing to make progress with potential partners regarding both Clevegen and Traumakine, whilst also exploring funding opportunities to ensure we can continue to progress both products. I would like to thank our shareholders for their continued belief in the Company and the management team and all the employees at Faron for their hard-work and dedication during this challenging year and look forward to updating the market on our progress throughout the course of 2021.

A virtual briefing and Q&A session for analysts will be hosted by Dr. Markku Jalkanen, Chief Executive Officer, and Toni Hänninen, Chief Financial Officer, at 12:00 pm GMT
https://www.lsegissuerservices.com/spark/FaronPharmaceuticalsOy/events/04110470-3c65-4dad-ba56-54b27e83f27f

Updated Bex page too - Data from MATINS have shown that bexmarilimab has the potential to be the first macrophage immune checkpoint therapy.

Bexmarilimab is currently in phase I/II clinical development as a potential therapy for patients with untreatable solid tumours. The MATINS study is a first-in-human open label phase I/II clinical trial investigating the tolerability, safety and efficacy of bexmarilimab in ten different hard-to-treat metastatic or inoperable solid tumour cohorts – cholangiocarcinoma, colorectal cancer, cutaneous melanoma, ER+ breast cancer, gastric cancer, hepatocellular carcinoma, ovarian cancer, uveal melanoma, pancreatic cancer and anaplastic thyroid carcinoma – which are all known to host a significant number of Clever-1 positive TAMs.

Part I (completed) of the trial dealt with tolerability, safety and dose escalation. The ongoing Part II is focused on identifying patients who show an increased number of Clever-1 positive TAMs and exploring safety and efficacy. Part III will be focused on assessing efficacy.

Data from MATINS have shown that bexmarilimab has the potential to be the first macrophage immune checkpoint therapy. To date, the investigational therapy has been shown to be safe and well-tolerated, making it a low-risk candidate for combination with existing cancer therapies, and has demonstrated early signs of clinical benefit in patients who have exhausted all other treatment options.

In the ongoing Part II of the trial, six solid tumour cohorts – cutaneous melanoma, colorectal cancer, hepatocellular cancer, ovarian cancer, cholangiocarcinoma (also known as bile duct cancer) and gastric cancer have demonstrated early signs of clinical efficacy from bexmarilimab therapy.

Nice update on the pipeline page .
Still good to see REMAP as a phase 3 status . I know its Q3 expected results , but that could be the catalyst for EUA and SSV .

Yes hopefully get some tidbits tomorrow too .

Oh well , yes , we've been waiting for a cracking RNS to shoot us up , but this one didn't do it today .
12-16% is always nice , but not what we deserved .

But in fairness , the RNS was just confirmation that Bex works to the degree that it was supposed to .

So from 67 patients - over 100 days - 48 end up dead ( 71% overall ) . You can't really sugar coat the fact that we are dealing with some very ill people here .

We can assume from what Markku has said before , that many of these patients will have had multiple therapies already which will have worn down their immune system , and who are pretty much having the last throw of the dice .

So in a trial where only 29% lived , almost half of those were receptive to Bexmarilimab , and those that did also pretty much all lived ( at least to the end of the trial ). Whether that will explain that the ones who died were in such a bad way that they were almost beyond saving , and that Bex works more effectively when given earlier in the treatment stages , who knows , but I guess that would apply to pretty much all therapies .

They slipped in that the Uveal cohort didn't show much efficacy - that was a disappointment , as Markku had sounded quite upbeat on that one in previous interviews .

But the fact that we now have 6 , and counting , cohorts that have showed excellent results , with 3 still to go , and now the increased frequency and dosing to add to the mix , it it sure gathering pace .

They are excited -

So , its left to us to ponder whether the market didn't really get it , or that we've had so many promises of Shareholder value , that the market is going to want to see some $ valuations in an RNS before it takes the handbrake off . And that's fair enough .
CFO Toni is excited , lets hope it's because he can finally see the light at the end of the tunnel , and is looking forward to the day when he can check the Faron bank account , and has to resize the screen cos theres too many noughts .

Alliance News :
Faron Pharmaceuticals, up 12% at 350.25p, 12-month range 216.05p-595p. The Finland-based biopharmaceutical company notes data which showed "significant survival benefit" in patients responding to cancer treatment bexmarilimab. Company says this is "very exciting data" supporting bexmarilimab's unique mechanism of action and adding to the accumulating evidence of bexmarilimab's broad potential across a range of hard-to-treat cancers.

No one should be selling on the news today - so much more to come - this is just another step up the ladder .

Nice that the CFO is excited .

I think the good news will keep flowing Zum , and yes the Interferon story is only getting started . Regardless of how long it takes the I/V delivery method to get proven up , we have that patented freeze dried commercial manufacturing process for IFN Beta1a being rolled out . That alone will be cash cow for decades to come .

Try being an ODX , AVCT and NCYT holder ( as quite a few are probably ) . It like playing chess with 3 people .

I think they are just scratching the surface of what the drug can do .
Personally I have a feeling the higher frequency and dosing may get much better results .

Only disappointment is that because they have had to rely on pateints who are pretty much at the end of the road , they are having to trial on patients whose immune system is mostly knackered , and often will die .

If they start being able to treat patients early on - before their immune systems are compromised , again I'd think the results would be even better .

Significant survival benefit observed in patients responding to bexmarilimab treatment with risk of death reduced by 88%
- Gastric cancer becomes sixth tumour cohort to show early signs of clinical efficacy
- Data monitoring committee recommends dose escalation expansion in all six cohort types besides ongoing colorectal cancer .

I think we can safely agree we have now entered the SSV zone .

Its a goodun !!

Interesting listening to his Traumakine comments .
First slide actually focused on Organ protection .
Talking about steroids , he highlighted that the corticosteroid use actually resticts the pathways for the patients own IFN Beta response , let alone the Traumakine . I never actually thought of it that way , but its totally logical that it would .

Hibiscus could really show up some interesting data , both on the IFN Beta and the steroid side .

Lots of important data coming . Still got Q1 showing up there for Matins summary data .

I can see one of these labs outside every major stadium . Not to test everybody as they come in - but just for those that get a positive read on an LFT - get put through the mobile PCR to get quick confirmation of what the LFT has detected ?

A quiet day again , but some strange activity towards the end . Price creeps up in the UK , with a few chunky Lago buys , then the Nas price gets pushed down by 2.5% right at the end . Still lowish volumes , but past history has showed that quite often before a substantial rerate - comes some downward shenanigans .

I'm not a believer in them , but these days I'll take anything as a good sign . 2 x 1 codes gone through . Is it happening ??

Like the parrot , success here is nailed on !

I'm the eternal optimist , but also realise that the can has been kicked down the road ( in as much as shareholder value ) .
One important point though is that can has been getting larger as it gets kicked along . Maybe we should think of it as rolling a snowball to make a snowman ?

2 years ago , it was hints about partner discussions that kept us dreaming.
Then it was Traumakine getting fast racked with global trials.
Now its Bexmarilimab getting to a deal brokering position , and the revealing of a growing relationship with America .

I feel for those who may have been really banking on a payday this quarter . We have Santhi who is waiting for a possibly life changing treatment . I'm just gonna buy a nice car hopefully . So we are all in different positions .

If I've learned anything in the last 3 years , its that shares rarely do what you hope , when you want . Otherwise we'd all be millionaires .
This share could go pop any day - but then I think that about EUA ( and thats been waiting to pop since last February ) .
Unless we get some dire news about things , I'm just gonna sit on my shares until it happens .

At the moment , I don't see any reason why Faron won't do some deals , and make some big money for us . But as for when , thats out of our hands , and even Markkus if the science and the data aren't ready to present . He obviously though that something could happen this quarter - but then we get a placing and further giggling around with dosing and frequencies . So the snowball gets rolled a bit further along I guess .
They are getting a lot of data coming in , I just think its taking more time than expected to see what they've got . And maybe its taking the partners longer to see what the role Clever 1 really means to the cancer industry . All these discoveries are very recent ( in pharma terms ) .
If people can't wait , selling £3.20 would be a loss for many , so my advice , leave as much in as you can for at least the next 3 months , otherwise it might be like seeing your lottery numbers come up , and you'd forgotten to buy the ticket .

Great positive read - I must admit I have to defer to the experts here when it comes to the nitty gritty - but even a thicko like me can see it bodes well !!

I'm not 100% clued up about manufacturing masks , so I assume it may be an issue having a logo on the mask itself that would differentiate it - i.e a Cu nano anti viral logo - something to stand out .
But if RMS are trying to build up sales on the retail end , it needs a ' look ' to separate it from any other mask .

I'm OK with what they have done so far - but they really need to highlight the Cu Nanoparticle - patented difference .
Even if thats in the packaging , or on point of sale marketing material .

Advertising costs money , and although RMS have cash - it can soon disappear .

So get on local radio - use the University connections - the Govt support etc , and the USP .

So many masks I see out and about are absolute rubbish - there is no standard .
You can literally walk around with a pair of underpants on your head .

Hopefully as we start opening up the country again , local and national media will take a fresh look at what a mask actually is , what is acceptable , and what are the best options .

Word of mouth will get you so far , but highlighting the pitfalls of wearing a inadequate face covering in the national press is what we need .